To ensure the implementation of the ACTG’s scientific, therapeutic, and pathogenesis-based research agenda, ACTG has a number of executive, scientific, and resource committees. While each committee has a specific objective, the overarching goal of all the committees is to ensure the network’s scientific agenda remains at the forefront of our research and to prioritize new and emerging scientific insights applicable to our patient populations.

Leadership and Operations Center

The ACTG Leadership and Operations Center (LOC) Administrative Core comprises Grants & Contracts, Budget & Finance, and Leadership Support teams and is housed within the Division of Infectious Diseases at University of California Los Angeles (UCLA). The Administrative Core is responsible for:

  • Managing all funds awarded to the LOC and Laboratory Center (LC)
  • Developing budgets; negotiating and executing contracts on behalf of the LOC and LC; and monitoring spending and financial activity on all LOC and LC awards
  • Maintaining all LOC and LC administrative and fiduciary records
  • Managing conference support for annual ACTG network meetings and leadership and scientific retreats
  • Maintaining the financial conflict of interest (FCOI) disclosure program
  • Tracking ACTG publications and ensuring compliance with NIH open access requirements
  • Preparing annual progress reports and other administrative reports to the NIH Division of AIDS (DAIDS)
  • Providing administrative and financial support to the ACTG Executive Committee (AEC)
  • Coordinating ACTG external communications, social media, and press releases

The Administrative Core is led by the LOC Executive Director, Alexis R. Sexton and reports to the ACTG Network Leadership Steering Committee (LSC).

Executive Committee & Network Leadership Steering Committee

The ACTG Executive Committee (AEC) is the primary governing body of the ACTG, with ultimate responsibility for all scientific, administrative, and fiscal decisions on behalf of the Network. Along with its key committees, the AEC oversees the overall fiscal management of the ACTG; develops network bylaws, policies, and procedures; establishes performance standards for network Centers and sites; ensures timely analysis and dissemination of study results; and works to enhance representation of underserved populations and participation by minority investigators in ACTG studies. The AEC is responsible for approving the leadership and membership of ACTG scientific and supporting committees.

The ACTG Network Leadership Steering Committee oversees the administrative, scientific, and laboratory management of the ACTG and provides guidance to and coordinates the activities of the Leadership and Operations Center (LOC), the Network Coordinating Center (NCC), and the Statistical and Data Management Center (SDMC).

Currier Headshot 2019

Judith S. Currier, MD, MSc (Chair)

Joseph Eron

Joseph Eron, MD (Vice Chair)

Scientific Agenda Steering Committee

The Scientific Agenda Steering Committee oversees all aspects of the development, refinement, and conduct of the ACTG’s scientific agenda and research plan, ensuring a clinical research agenda that addresses the National Institute of Allergy and Infectious Diseases (NIAID) scientific priorities and that responds to changes in the field.

Joseph Eron

Joseph Eron, MD (Chair)

Behavioral Science Subcommittee of the SASC

The Behavioral Science Subcommittee works closely with all of the ACTG transformative science groups and collaborative science groups in protocol development. The subcommittee has members from a wide array of behavioral science expertise who work together to ensure that the most rigorous behavioral science methods will be used to enhance the objectives OF ACTG studies.


Jane Simoni, MD (Chair)

Balan, Ivan

Ivan Balan, PhD (Vice-Chair)

Data Management Committee

The Data Management Committee works closely with the ACTG Data Management Center to develop and implement standardized electronic data collection methods and case report forms. The committee provides clinical, data management and analysis expertise to ensure collection of appropriate data from US and international sites to address data needs of ACTG clinical trials. The committee also aims to coordinate data collection methods of the ACTG with those of other NIAID/DAIDS networks to ensure consistent and standard data collection.

Chad Achenbach

Chad Achenbach (Chair)

Performance Evaluation Committee

The Performance Evaluation Committee (PEC) monitors the performance of all key elements of the ACTG to ensure efficient development, implementation, and completion of clinical trials and the publication of study results. Through a continuous cycle of monthly reviews and interim and annual evaluations, the PEC assesses the structural components of the ACTG including the Leadership Operations Center (LOC); Network Coordinating Center (NCC); Statistical and Data Management Center (SDMC); specialty and site laboratories; and clinical research sites (CRSs).

The committee also identifies potential issues and obstacles to performance, provides real-time technical support and assistance, and makes recommendations to the ACTG Executive Committee for process improvements to facilitate the efficient execution of the Network’s scientific agenda. The PEC draws insight and expertise from a membership that encompasses the Network’s CRSs, laboratories, SDMC, NCC, and community representatives.

Susan Koletar

Susan Koletar (Chair)

Constance Benson (Vice Chair)

Underrepresented Populations Committee

The Underrepresented Populations Committee promotes and monitors the clinical trial participation of groups traditionally underrepresented in clinical research, and recommends strategies through which the ACTG Executive Committee can enhance the participation of underrepresented populations and minority investigators in HIV/AIDS research. The definition of underrepresented populations includes—but is not limited to—racial and ethnic minorities, women, transgender persons (and other sexual and gender minorities), individuals who use drugs, persons who face barriers to adherence, and individuals with disabilities. Membership in the committee is updated regularly and comprises elected members and representatives from other committees and stakeholders within the ACTG. The committee also oversees the selection of candidates for the ACTG Minority HIV Investigator Mentoring Program (MHIMP) and the ACTG International HIV Investigator Mentoring Program (IHIMP).

Roberto Arduino

Roberto Arduino (Chair)

Maile-Karris (1)

Maile Karris  (Vice Chair)

Comorbidities Transformative Science Group

People living with HIV, even when highly adherent to treatment, are at increased risk for several end organ diseases, including cardiovascular disease, diabetes, hypertension, chronic kidney disease, osteoporosis, neurocognitive impairment, and declines in physical function. HIV-associated alterations in immune function and persistent inflammation appear to contribute to the excess risk of these diseases.

The End-Organ Disease and Inflammation Transformative Science Group (TSG) fosters collaboration among virologists, immunologists, pharmacologists, and clinical and laboratory researchers to design clinical trials of novel interventions targeting end-organ diseases that contribute to increased morbidity and mortality among people with HIV. The TSG also conducts observational studies using existing ACTG data and samples to evaluate the causes and consequences of these end-organ diseases and the role of HIV infection; interventional studies of other host-targeted therapies designed to enhance immune recovery; and studies to understand the influence of other key factors, such as age, race, and sex, on the clinical consequences of HIV infection.

Netanya Utay

Netanya Utay (Chair)

Kristine Erlandson

Kristine Erlandson (Vice Chair)


Antiretroviral Therapy Strategies Transformative Science Group

The Antiretroviral Therapy Strategies Transformative Science Group oversees ACTG studies evaluating the effectiveness of novel treatment strategies — including long-acting antiviral drugs and formulations, broadly neutralizing and other monoclonal antibodies, and novel combinations of biomedical and behavioral modalities — in sustaining virologic suppression and engagement in HIV care globally. The TSG also:

  • Creates partnerships to evaluate promising treatment delivery technologies, interventions, and strategies
  • Evaluates pharmacokinetic interactions between antiviral agents and other compounds
  • Partners with other networks to strengthen or broaden the evaluation of novel treatment strategies with HIV prevention applications
  • Assists as needed in the evaluation of novel therapeutic agents for emerging infectious diseases.
Timothy Wilkin

Timothy Wilkin  (Chair)

Monica Gandhi (Vice Chair)

Hepatitis Transformative Science Group

The ACTG Hepatitis Transformative Science Group facilitates trials of novel therapeutics in liver disease of people living with HIV infection, including liver disease related to hepatitis B virus (HBV) and hepatitis C (HCV) infection and metabolic disorders. Specifically, the TSG:

  • Interacts with companies with promising therapeutic compounds (e.g. antivirals, antifibrotics) to determine the best approach to developing an understanding of the efficacy and safety of the drug or combinations of drugs and to consider unique patient populations relevant to the ACTG mission. The TSG also considers the incorporation and validation of predictive and prognostic candidate biomarkers for each drug regimen.
  • Encourages and facilitates collaboration between laboratory and clinical scientists, experts in virology, immunology, pharmacology, and genetics, and industry partners, in order to facilitate rapid protocol development and study enrollment.
  • Educates ACTUs about candidate selection, drug-drug interactions, and end-stage liver disease.
  • Works to ensure that ACTG studies of these novel agents represent the face of HIV in the U.S. and internationally by encouraging the participation of underrepresented individuals, including women and persons of color.
  • Encourages the training of the next generation of hepatitis researchers with particular focus on international investigation.
The David Geffen School of Medicine at UCLA  - UCLA Care Event, Luskin Conference Center, UCLA, Los Angeles, CA.
December 6th, 2019
Copyright Don Liebig/ASUCLA

Debika Bhattacharya (Chair)

Arthur Kim

Arthur Kim (Vice Chair)

HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group

Even after treating HIV with potent antiretroviral medications, the virus persists in some cells (“the HIV reservoir”), where it hides from the immune system. Our ultimate goal in the Cure TSG is to cure HIV either through the complete elimination of the HIV reservoir (“sterilizing cure”) or by controlling the virus in the absence of antiretroviral treatment (“functional cure”).

The Cure TSG scientific priorities are to:

  • Fully characterize the HIV reservoirs in blood and tissues
  • Identify and validate methods to quantify the HIV reservoir, which then can be used in clinical trials that target it
  • Understand by what means people have been cured of HIV infection after bone marrow transplantation (The Berlin and the London patients), and try to replicate them if possible
  • Better understand the mechanisms that maintain the HIV reservoir and how they relate to immune activation and immune exhaustion
  • Identify the most promising new therapies to cure HIV and evaluate them in pilot “proof-of-concept” cure studies

The complexity of HIV persistence and curing HIV requires a broad approach that involves TSG members and guest scientists from many different disciplines, both within and outside the ACTG, and from academia and industry.


Marina Caskey (Chair)

Katharine Bar

Katharine Bar (Vice Chair)

Tuberculosis Transformative Science Group

The Tuberculosis (TB) Transformative Science Group is responsible for development, implementation, and oversight of the ACTG research agenda related to the treatment and prevention of TB with and without HIV co-infection. The primary objectives of the TB TSG are to:

  • Develop shorter, safer treatment regimens for drug-susceptible and resistant TB disease
  • Identify optimal TB preventive therapy for drug-susceptible latent TB infection and household contacts exposed to multi-drug resistant TB
  • Identify regimens for the treatment of TB meningitis and isoniazid-monoresistant TB (areas of high unmet medical need)
  • Optimize TB treatment and prevention in TB/HIV co-infected people

Additional aims include conducting transformative research to:

  • Describe drug-drug interactions involving anti-TB therapy and ART
  • Improve TB diagnostic assays and biomarkers to predict and detect disease and to monitor response to therapy
  • Develop novel TB clinical trial designs
Kelly Dooley

Kelly Dooley (Chair)

Payam Nahid

Payam Nahid (Co-vice Chair)

Vidya Mave

Vidya Mave (Co-vice Chair)

Women's Health Collaborative Science Group

Women represent large proportions, and in many regions of the world, a majority of people living with HIV infection. Yet, they are often underrepresented in HIV research. The Women’s Health Inter-Network Scientific Committee (WHISC) works to develop optimal strategies for the treatment of HIV disease and related complications among women. To this end, the WHISC develops studies that address scientific questions of high importance to the health of women living with HIV. It also seeks to optimize recruitment, retention, and sex-specific analyses of women in clinical trials. It advises the ACTG on clinical trial language and makes recommendations regarding reproductive, contraception, and pregnancy issues. It serves as a liaison with other networks, groups, and agencies involved in the care and treatment of women to enhance communication and avoid duplication in clinical trials. Finally, the committee seeks to mentor junior faculty with careers directed at research into the health of women living with HIV. The current WHISC scientific agenda seeks to:

  • Assess optimal therapy of HIV/AIDS, TB, hepatitis, and ‘cure’ strategies in women living with HIV over the course of their lifetime
  • Identify critical drug-drug interactions between hormonal therapies and antiviral drugs, TB drugs, hepatitis treatment, and cure interventions in women living with HIV
  • Determine sex differences in comorbidities (e.g., cardiovascular disease, depression, obesity, aging) and responses to their treatments in people living with HIV
Rosie Mngqibisa

Rosie Mngqibisa (Chair)

Risa Hoffman

Risa Hoffman (Vice Chair)

Neurology Collaborative Science Group

The areas of highest priority for investigation by the Neurology CSG include:

  • HIV-associated cognitive impairment
  • HIV eradication and the central nervous system as a reservoir of HIV infection
  • Mental health and behavior of women and men living with HIV
  • HIV-associated CNS opportunistic infections
  • Neurologic toxicities of ARV and other drugs
  • Distal sensory peripheral neuropathy

Membership in the Neurology CSG comprises academic neurologists, psychiatrists, pharmacologists, virologists, and infectious diseases specialists. The committee includes working groups addressing HIV and aging, virology, mental health, women’s issues, and HIV cure.

Beau Ances

Beau Ances (Chair)


Felicia Chow (Vice Chair)

Global Community Advisory Board

The ACTG Global Community Advisory Board (GCAB) supports community outreach, education, and participation in research, and represents community concerns in the ACTG. Comprised of a member from the CAB at each ACTG Clinical Research Site (CRS), the GCAB works to integrate community involvement into site plans and operations to advance HIV/AIDS research. The GCAB provides an opportunity for affected communities, and especially for the participants in ACTG clinical trials, to:

  • Better understand the clinical research process
  • Voice questions or concerns regarding clinical studies, their development, implementation and outcomes
  • Contribute their knowledge, perspective, and experience to efforts to enroll and retain trial participants
  • Advocate on behalf of clinical trial participants
  • Volunteer for protocol teams and subcommittees
  • Mentor new members and ask for mentorship when needed
  • Help keep research in the forefront of technology/communication systems
  • Ensure that trial materials are available in all appropriate languages
  • Promote ethical research practices
Orbit Head Shot UN Faith Breakfast

Orbit Clanton (Chair)


Jan M. Kosmyna M.S., B.Ed., R.N (Vice Chair)

Community Scientific Subcommittee (CSS) of the GCAB

GCAB members are selected by their CABs and serve two-year terms. CGAB members may also be selected to serve on the non-scientific ACTG committees. Participation by the community on ACTG committees and protocol reviews is conducted through the Community Scientific Subcommittee (CSS) of the GCAB.


Martha Tholanah (Co-Chair)


Scovia Aseru (Co-Chair)

Site Management & Clinical Care

The Site Management & Clinical Care Committee (SMCCC) oversees logistical processes essential for successful implementation and completion of the ACTG scientific research agenda. The mission of the SMCCC is to provide practical advice and technical expertise in the areas of patient care, data collection and management, and site operations as they relate to the safe and successful execution of ACTG clinical trials. The SMCCC is composed of site coordinators, research nurses, regulatory and data management personnel, pharmacists, and representatives of allied organizations including the NIH Division of AIDS (DAIDS), the Frontier Science Technology and Research Foundation (FSTRF), and community representatives.
The SMCCC is comprised of two subcommittees and six working groups:

  • Protocol Development and Implementation Subcommittee (PDISC)
    • Field Representatives Working Group
    • Outreach, Recruitment and Retention Working Group
    • Pharmacy Working Group
  • Site Operations Subcommittee (SOS)
    • Data and Quality Management Working Group
    • Study Coordinators Working Group
    • Training and Education Working Group

Wilifred Gurupira (Co-Chair)


Tanisha Sullivan (Co-Chair)

Laboratory Steering Committee

Grace Aldrovandi

Grace Aldrovandi (Chair)

Alan Landay

Alan Landay (Vice Chair)

Laboratory Technologist Committee

Francoise Giguel

Francoise Giguel (Chair)

Sikhulile Moyo

Sikhulile Moyo (Vice Chair)

Repository Advisory Group

Grace Aldrovandi

Grace Aldrovandi (Chair)

Network Coordinating Center

The ACTG Network Coordinating Center (NCC), housed at Social & Scientific Systems, Inc. (SSS), collaborates with ACTG leadership to provide technical, scientific, and administrative support for the network. The NCC facilitates implementation of the ACTG scientific research agenda, harmonizes network responsibilities, and ensures compliance with policy and procedures among ACTG leadership, sites, and partners. Among its responsibilities, the NCC provides:

  • Administrative, management, technical, and clinical support for the network leadership, committees, and sites, and for community advocates and representatives
  • Support for protocol development and implementation; laboratory structure development, quality assurance, and training; site capacity development, assessment, training and quality assurance; and publication of ACTG research
  • Support for network communications, including quality assurance for information stored on the network’s Management Information System (MIS) and secure web-based document management system, integration with Network websites, and coordination with other DAIDS-funded networks
  • Management of study protocol development including protocol documents, manuals, and safety monitoring

As an ACTG Network Consortium Partner, the NCC Director is a member of the ACTG Executive Committee (AEC).

1554843413251 (002)

Doreen Collins (Chair)

Statistical and Data Analysis Center (SDAC)

Senior-level biostatisticians at the Statistical and Data Analysis Center (SDAC) provide complete statistical support, from study design through data analysis and publication for phase I through Phase IV clinical trials, diagnostic studies and observational studies.

These biostatisticians:

  • Are among the leading experts in clinical trial design and analysis and are associated with the Harvard T.H. Chan School of Public Health
  • Are core members of each protocol team, providing statistical expertise from study inception through publication
  • Take a leadership role in designing, conducting and reporting results from clinical trials and observational studies
  • Prepare and present interim analyses of data from clinical trials to independent Study Monitoring Committees and Data and Safety Monitoring Board
  • Lead self-initiated research including within-study and cross-study data analysis to address important clinical research questions, and clinical trial and observational study methods research
  • Mentor and train the next generation of statistician-trialists, and investigators from international collaborating research sites interested in quantitative sciences applied to HIV and other infectious diseases research
Michael Hughes

Michael Hughes (Chair)

Data Management Center (DMC)

The ACTG Data Management Center (DMC) at Frontier Science Foundation acts as liaison between the team and the clinical sites concerning all aspects of data required during a study. The DMC supports each ACTG protocol team by:

  • Facilitating the design and development of electronic case report forms to optimize study data collection
  • Participating in protocol- and site-specific training
  • Monitoring the timeliness and quality of study data, and working with sites to address any issues or delinquencies
  • Providing advice and instruction to sites in the accurate completion of study forms
  • Preparing data for annual FDA progress reports and other reports as needed
The David Geffen School of Medicine at UCLA  - UCLA Care Event, Luskin Conference Center, UCLA, Los Angeles, CA.
December 6th, 2019
Copyright Don Liebig/ASUCLA

Marlene Cooper (Chair)

Specialty Labs List

Lab Director

Laboratory Name

Lab Contact/s

Lab Address

Area of Interest

Sara Gianella, MD

San Diego Virology Specialty Laboratory Sara Gianella, MD | Stein Clinical Research Building
9500 Gilman Drive, MC 0679
La Jolla, CA 92093
Translational Virology, HIV persistence, proviral sequencing, biomarkers, co-infections

Jonathan Li

Harvard/Brigham Virology Specialty Laboratory Jonathan Li | Li Laboratory
65 Landsdowne Street, Rm 435
Cambridge, MA 02139
Viral persistence, resistance and evolution

Nilu Goonetilleke

UNC-Immunology Specialty Laboratory (UNC-ISL) Nilu Goonetilleke | (PI)
Yinyan Xu | (UNC-ISL Lab Manager)
Genetic Medicine Building
120 Mason Farm Road, Room 2023A
Chapel Hill, NC 27599
Human T cell immunology, Infectious Disease, Vaccinology

Cheryl L. Day, PhD

Emory Immunology Specialty Laboratory Cheryl L. Day, PhD | Emory Vaccine Center
954 Gatewood Rd NE, Room 1054
Atlanta, GA 30329
HIV, TB, Cellular Immunology, Immune Correlates, Translational Immunology, Vaccines

Gary Maartens

UCT PK Laboratory, Division of Clinical Pharmacology Sandra Castel |
Gary Maartens |
Lubbe Wiesner |
K50 Old Main Building
Groote Schuur Hospital, Observatory, 7925
Cape Town, South Africa
TB and HIV

John W. Mellors

University of Pittsburgh Virology Specialty Lab Director | John W. Mellors, M.D |
Co-Director | Urvi M. Parikh, PhD |
Co-Director | Joshua Cyktor, PhD |
Scaife Hall, Suite 818
University of Pittsburgh School of Medicine
3550 Terrace Street
Pittsburgh, PA 15261
HIV Remission & HIV Drug Resistance
Antiviral Pharmacology Laboratory Fletcher, Scarsi and Podany | Associate Directors
Lee Winchester, lab manager | 402-559-1345 |
UNMC Center for Drug Discovery
University of Nebraska Medical Center
986120 Nebraska Medical Center
Omaha, NE 68198-6120
Pharmacologic reservoirs for HIV and viral persistence; antiretroviral therapy and PKPD characteristics; tuberculosis and management of concomitant medications; women’s health.

Charles Rinaldo

Bernard Macatangay

University of Pittsburgh Immunology Specialty Lab Charles Rinaldo | Phone 412-624-3928 |
Bernard Macatangay | Phone 412-383-1272 |
Division of Infectious Diseases
University of Pittsburgh School of Medicine
8th Floor Scaife Hall
3550 Terrace St, Pittsburgh, PA 15261
Viral immunology and immunotherapy

Peter Anderson

Jennifer Kiser

Colorado Antiviral Pharmacology Laboratory Peter Anderson |
Jennifer Kiser |
University of Colorado| Anschutz Medical Campus
12850 E. Montview Blvd
Aurora, CO 80045
Antiviral Clinical Pharmacology, adherence biomarkers, PrEP, viral hepatitis, special populations with HIV